What changes did apotex make to ruxolitinib's formulation?

What formulation changes did Apotex make for ruxolitinib?

Apotex’s specific changes to the ruxolitinib formulation (for example, differences in tablet composition, coatings, excipients, dissolution/particle properties, or manufacturing process) are not provided in the information available here. Without the underlying document or claim text that describes Apotex’s formulation work, I can’t accurately state what changed.

Where to find the exact formulation-change details

To identify “what changes” Apotex made, you generally need one of the following:
- The relevant patent/application describing Apotex’s formulation or ruxolitinib generic product changes.
- The regulatory filing or technical dossier (often including composition and in vitro dissolution information).
- A lawsuit or regulatory dispute document quoting the exact differences (common in patent litigation summaries).

Can you share the source you’re looking at?

If you paste or upload the excerpt (or provide a link/title to the document) that mentions Apotex and ruxolitinib, I can extract and summarize the exact formulation changes it describes, including the specific components/process terms used.